Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
boston blog main
clinical trials
4
×
life sciences
4
×
national blog main
boston top stories
drugs
alnylam pharmaceuticals
boston
new york
new york blog main
new york top stories
rna interference
accelerated approval
acute hepatic porphyria
aldehyde
aldeyra therapeutics
alirocumab
allergan
allergic conjunctivitis
amgen
aminolevulinic acid
biotech
bristol-myers squibb
clinical data
dry eye disease
evercore isi
evolocumab
genfit
gilead sciences
givosiran
heart attack
inclisiran
intercept pharmaceuticals
joseph swartz
ldl-c
liver
liver disease
madrigal pharmaceuticals
mark pruzanski
medicines co.
What
data
4
×
drug
new
4
×
medicine
alnylam
pharmaceuticals
rna
aldeyra
approved
based
cholesterol
cleared
closer
disclosed
disease
evidence
eye
far
fatty
fda
fighting
filing
heart
horizon
inflammation
intercept
interference
known
lasting
liver
long
looms
lowering
market
marketed
medco
medicines
multiple
nasdaq
nash
Language
Current search:
new
×
photo
×
" life sciences "
×
" clinical trials "
×
data
×
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug